New drug combo shows promise for hard-to-treat HER2 cancers

NCT ID NCT06271837

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by surgery or have spread will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS (EXCLUDING GASTRIC CANCER AND BREAST CANCER)

Contacts and locations

Locations

Research Site

Beijing, 100142, China
Research Site

Beijing, 100191, China
Research Site

Changchun, 130021, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610041, China
Research Site

Chongqing, 400030, China
Research Site

Dongyang, 322100, China
Research Site

Guangzhou, 510145, China
Research Site

Guangzhou, 510630, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310016, China
Research Site

Hangzhou, 310022, China
Research Site

Harbin, 150081, China
Research Site

Hefei, 230031, China
Research Site

Kunming, 650118, China
Research Site

Lishui, 323000, China
Research Site

Nanchang, 330029, China
Research Site

Shandong, China
Research Site

Shanghai, 200001, China
Research Site

Shanghai, 200011, China
Research Site

Shanghai, 200032, China
Research Site

Shenyang, 110016, China
Research Site

Taiyuan, 030001, China
Research Site

Wuhan, 430022, China
Research Site

Xi'an, 710061, China
Research Site

Xuzhou, 221009, China
Research Site

Yinchuan, 750004, China
Research Site

Zhengzhou, 450002, China
Research Site

Zhengzhou, 450008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.